Stocks of Evelo Biosciences Inc (NASDAQ:EVLO) traded higher last session on Wall Street, up 65.05% to $0.73.
According to the data, Evelo Biosciences Inc (NASDAQ:EVLO) has 2 analysts covering its stock. The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $10.00, we find $10.00. Given the previous closing price of $0.45, this indicates a potential upside of 2122.22 percent. EVLO stock price is now -72.40% away from the 50-day moving average and -86.99% away from the 200-day moving average. The market capitalization of the company currently stands at $13.91M.
A total of 1 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $10.00 as their price target over the next twelve months.
With the price target maintained at $12, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Evelo Biosciences Inc (NASDAQ: EVLO).
In other news, Bodmer Mark, CSO, President of R&D sold 3,163 shares of the company’s stock on Nov 08. The stock was sold for $1,044 at an average price of $0.33. Upon completion of the transaction, the CSO, President of R&D now directly owns 25,732 shares in the company, valued at $18784.36. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 08, Chief Medical Officer McHale Duncan sold 3,103 shares of the business’s stock. A total of $1,024 was realized by selling the stock at an average price of $0.33. This leaves the insider owning 16,984 shares of the company worth $12398.32. Insiders disposed of 176,963 shares of company stock worth roughly $0.13 million over the past 1 year. A total of 50.78% of the company’s stock is owned by insiders.
Thursday’s opening bell rang with an opening price of $0.4647 for Evelo Biosciences Inc (NASDAQ: EVLO). During the past 12 months, Evelo Biosciences Inc has had a low of $0.30 and a high of $48.00. The fifty day moving average price for EVLO is $2.6621 and a two-hundred day moving average price translates $5.6487 for the stock.
The latest earnings results from Evelo Biosciences Inc (NASDAQ: EVLO) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$3.78, missing analysts’ expectations of -$3.3 by -0.48. This compares to -$5.66 EPS in the same period last year. The company reported revenue of $11.18 million for the quarter, compared to $29.05 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -61.51 percent.
Evelo Biosciences Inc(EVLO) Company Profile
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
